Spikevax (previously COVID‑19 Vaccine Moderna)
A Conditional Marketing Authorisation (CMA) has been granted in the EU for the product Spikevax (previously COVID‑19 Vaccine Moderna) to prevent coronavirus disease 2019 (COVID‑19) in people from 6 years of age.
Patient Information Leaflet
Patient Information Leaflet
Summary of Product Characteristics
Summary of Product Characteristics
Contact Moderna
8am-5pm CET – Mon - Fri
EMEAMedinfo@modernatx.com